Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6011
pubmed:dateCreated
1976-6-2
pubmed:abstractText
The effect of a six-week course of spironolactone 300 mg/day was examined in 25 unselected patients with essential hypertension. In the blood spironolactone produced a significant rise in urea and potassium concentrations and a fall in sodium and bicarbonate concentrations. In six patients blood pressure was normal at the end of the course, while in five patients there was almost no change. Studies of the effects of spironolactone on various indices usually affected by mineralocorticoids-namely, blood electrolytes, total body potassium, and rectal electrical properties-showed no differences between responding and non-responding patients. Mineralocorticoid excess therefore seems to be rarely responsible for essential hypertension and the influence of spironolactone cannot at present be fully explained.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-1126134, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-1132803, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-1147737, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-237802, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-4136047, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-4195768, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-4338668, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-4372447, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-4683735, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-47018, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-4829862, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-4879007, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-5001931, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-5017240, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-5069733, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-5082464, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-5134893, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-5332539, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-5428856, http://linkedlifedata.com/resource/pubmed/commentcorrection/766908-5550136
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0007-1447
pubmed:author
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
682-4
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1976
pubmed:articleTitle
Spironolactone in essential hypertension: evidence against its effect through mineralocorticoid antagonism.
pubmed:publicationType
Journal Article, Clinical Trial